Marketing researchers spread thin, data show

Share this article:

Data indicate a noticeable step-up in the workload for market research pros based at pharmaceutical firms.

The primary research spend managed per full-time employee (FTE) increased significantly the last five years, from below $1 million in 2006 to nearly $1.4 million in 2010, figures from TGaS Advisors show. Data were presented at the Pharmaceutical Marketing Research Group Annual National Conference in March.

TGaS does not have a finite or generally accepted opinion about the right workload. It varies depending on the circumstances. But other industry sources say the optimal benchmark for FTE should be between $800,000 and $1 million per head. Why the heavier workloads the last few years? It's more a factor of manufacturers thinning out their ranks than shrinking MR budgets.

“Brand managers' demand for research hasn't really changed—the same issues have to be tracked,” explained TGaS's John Kain, VP, management advisor. “Our hypothesis is that budgets are tightened and headcount is shrunk or allowed to attrition accordingly—and then brand teams come up with funds for necessary research.”

TGaS derives the metric by dividing the total external market research spend per year by the number of FTEs managing those research projects. Calculations have included between eight and 11 benchmarks per year, Kain said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...